Home > Insider Trading > Filing (0001209191-21-057957)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
850261	Sorrento Therapeutics Inc.	SRNE	Biological Products, (No Disgnostic Substances) (2836)	330344842

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1518466	Kim Janda	C/O Sorrento Therapeutics, Inc. 4955 Directors Place San Diego CA 92121		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-09-27	35,000	$1.80	38,000	No	4	M	Direct
Common Stock	Acquisiton	2021-09-27	7,357	$3.57	45,357	No	4	M	Direct
Common Stock	Disposition	2021-09-27	42,357	$8.02	3,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options	Disposition	2021-09-27	35,000	$0.00	35,000	$1.80
Common Stock	Stock Options	Disposition	2021-09-27	7,357	$0.00	7,357	$3.57

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2027-09-15	No	4	M	Direct
27,643		2028-11-26	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.03, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
1/12 of the original number of shares subject to this option vested and became exercisable on October 15, 2017 and 1/12 of the original number of shares subject to the option vested following each one month of service thereafter.
1/12 of the original number of shares subject to this option vested and became exercisable on December 26, 2018 and 1/12 of the original number of shares subject to the option vested following each one month of service thereafter.